Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorphenamine + dextromethorphan + paracetamol
- Development stage
- Unknown
- Lead developer
- Grupo Farmasierra
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Remidol is a combination non-prescription drug developed and manufactured by Grupo Farmasierra. It is formulated as granules for oral solution and is indicated for the symptomatic relief of common cold and influenza symptoms, including mild to moderate pain, fever, non-productive cough, nasal congestion, and sneezing. The product contains three active ingredients: paracetamol (acetaminophen), which acts as an analgesic and antipyretic; dextromethorphan hydrobromide, a non-opioid antitussive that suppresses the cough reflex; and chlorphenamine maleate, a first-generation antihistamine that reduces nasal secretions and sneezing.
- Brand names
- Remidol
- Other names
- chlorphenamine + dextromethorphan + acetaminophenchlorphenamine + dextromethorphan + paracetamolchlorphenamine maleate + dextromethorphan hydrobromide + paracetamolchlorpheniramine + dextromethorphan + acetaminophenchlorpheniramine + dextromethorphan + paracetamolchlorpheniramine maleate + dextromethorphan hydrobromide + acetaminophen
02
Targets
HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SIGMAR1 (Sigma non-opioid intracellular receptor 1)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on chlorphenamine + dextromethorphan + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorphenamine + dextromethorphan + paracetamol.